MediWound’s core business is centered on enzymatic therapies with Nexobrid as the primary revenue driver, supported by increasing U.S. market penetration and manufacturing scale-up. The company’s technology and regulatory approvals provide moderate defensibility, though competitive enzymatic and wo…
MediWound (MDWD) Q1 2025: 207% U.S. Nexobrid Revenue Surge Highlights Manufacturing Scale-Up
MediWound demonstrated robust commercial traction with Nexobrid's U.S. revenue more than tripling year-over-year, driven by expanding burn center adoption. Clinical progress on EscharEx remains on track, supported by broad industry collaboration and advancing late-stage trials. Manufacturing scale-up and strategic U.S. facility planning position the company for sustained growth and enhanced market readiness.
Summary
- Industry Validation of EscharEx: Collaboration with nearly all leading wound care companies underscores strong clinical confidence.
- Manufacturing Capacity Expansion: New facility commissioning on schedule to support sixfold production increase by year-end 2025.
- Commercial Momentum: Nexobrid’s U.S. sales surged 207% YoY, reflecting deepening market penetration and emergency use recognition.
Business Overview
MediWound Ltd. is a biotechnology company specializing in enzymatic therapies for non-surgical tissue repair. Its primary products include Nexobrid, an FDA-approved biologic for enzymatic eschar removal in burns, and EscharEx, a late-stage investigational therapy targeting chronic wounds such as venous leg ulcers and diabetic foot ulcers. Revenue is generated through product sales, development service contracts, and strategic collaborations.
Performance Analysis
First quarter revenue totaled $4 million, down from $5 million year-over-year, primarily reflecting the completion phase of BARDA-funded development services related to Nexobrid. Despite this decline, gross profit improved to $0.7 million with a 19% margin, up from 12%, driven by a favorable shift in revenue mix toward product sales. Operating loss widened to $5.2 million, mainly due to increased R&D expenses of $2.9 million, reflecting intensified investment in the EscharEx VALUE Phase III trial. SG&A expenses were relatively stable at $3.1 million.
Notably, Nexobrid’s U.S. commercial partner Vericel reported a 207% year-over-year increase and 31% sequential growth in Nexobrid revenue, signaling strong market adoption. The company’s cash position stood at $38.7 million, with $5.1 million used in operating activities during the quarter, supporting ongoing clinical and manufacturing initiatives.
- Revenue Mix Shift: Decline in BARDA-funded services offset by rising product sales and improved gross margin.
- R&D Investment Acceleration: Increased spending underscores commitment to late-stage clinical development and regulatory readiness for EscharEx.
- Cash Utilization and Position: $38.7 million in liquidity provides runway for clinical trials and manufacturing scale-up.
The financials reflect a transitional phase with elevated clinical development costs balanced by growing commercial traction, particularly in the U.S. burn care market.
Executive Commentary
"The value-based risk study for EscharEx is on track, and our collaboration with Kerecis marks a significant milestone, bringing nearly all major wound care companies into our clinical research programs. Nexobrid continues to gain global traction as we advance long-term manufacturing investments to support sustained growth."
Ofer Gonen, Chief Executive Officer
"Gross margin improved to 19% due to a favorable revenue mix, while R&D expenses increased as we continue to invest in the EscharEx Phase III trial. Our cash position remains strong at $38.7 million, supporting our operational priorities."
Hani Luxenberg, Chief Financial Officer
Strategic Positioning
1. Clinical Development and Industry Collaboration
MediWound is executing a comprehensive global Phase III trial for EscharEx in venous leg ulcers, enrolling 216 patients across 40 sites with about half in the U.S. The company has secured participation from leading wound care companies such as Solventum, Mölnlycke, MIMEDX, and Kerecis, reflecting strong external validation. A planned Phase II head-to-head study against collagenase aims to bolster regulatory submissions and commercial positioning.
2. Commercial Expansion of Nexobrid
Nexobrid’s adoption in the U.S. has accelerated markedly, with nearly 60 burn centers ordering consistently. The 207% year-over-year revenue increase reported by Vericel highlights successful market penetration. International demand in Japan and Europe continues to outstrip current manufacturing capacity, underscoring the need for scale-up.
3. Manufacturing Scale-Up and U.S. Facility Planning
The new manufacturing facility in Israel is progressing on schedule, expected to reach full operational capacity by year-end 2025, enabling a sixfold increase in production. Regulatory inspections by EMA are anticipated sooner than FDA due to local inspectors. Additionally, MediWound is advancing BARDA-supported planning for a U.S.-based backup manufacturing site, with site selection expected by Q3 2025, aligning with growing governmental interest in domestic supply security.
4. Strategic Financial Management
The company’s financial strategy balances increased R&D investment with maintaining a solid cash runway. Non-cash financial income fluctuations tied to warrant revaluations introduce volatility below operating income but do not impact core operational funding. The company expects warrant-related volatility to cease post-November 2026.
5. Market Access and Pricing Strategy
MediWound is conducting health economics and outcomes research to support a premium pricing strategy for EscharEx versus collagenase, factoring in faster debridement, reduced healthcare utilization, and improved patient outcomes. This approach aims to maximize market access and reimbursement potential upon product launch.
Key Considerations
MediWound’s Q1 performance reflects a company at a strategic inflection point, balancing late-stage clinical development with expanding commercial execution and manufacturing scale-up.
- Clinical Trial Execution: Enrollment pace and site activations in the VALUE Phase III trial are progressing as planned, critical for mid-2026 interim data readout.
- Manufacturing Readiness: Timely commissioning of the new facility and regulatory inspections will be pivotal to meeting growing global demand.
- Governmental Engagement: BARDA support for U.S. manufacturing expansion and interest in stockpiling Nexobrid enhances strategic positioning in emergency preparedness.
- Revenue Composition Shift: Transition from BARDA-funded development services to product sales requires careful management to sustain revenue growth.
- Financial Volatility: Warrant revaluation impacts below operating income introduce earnings volatility but do not affect cash flow or operational execution.
Risks
MediWound faces execution risks related to clinical trial enrollment and outcomes, regulatory approval timelines, and manufacturing scale-up delays. The uncertainty of warrant revaluation impacts adds financial volatility. Additionally, reliance on governmental funding and stockpiling programs introduces exposure to policy shifts and budgetary constraints.
Forward Outlook
For Q2 2025, MediWound expects continued progress in clinical trial enrollment and manufacturing commissioning. Full-year 2025 revenue guidance remains reaffirmed at $24 million, incorporating Nexobrid sales growth and completion of BARDA-funded development services. Management anticipates operational readiness of the new manufacturing facility by year-end and plans to finalize U.S. backup facility site selection by Q3 2025.
- Q2 2025: Continued enrollment momentum and manufacturing commissioning progress.
- Full Year 2025: Revenue guidance maintained at $24 million with increased product sales offsetting declining development services.
Takeaways
MediWound’s first quarter results underscore a company advancing both clinical and commercial fronts while preparing for significant manufacturing capacity expansion.
- Commercial Traction: Nexobrid’s 207% U.S. revenue growth validates market adoption and supports confidence in scaling operations.
- Clinical Validation: Broad industry collaboration and robust trial design position EscharEx for regulatory success and competitive differentiation.
- Manufacturing Investment: On-schedule facility commissioning and strategic U.S. manufacturing planning mitigate supply constraints and support long-term growth.
Conclusion
MediWound’s Q1 2025 reflects a critical phase of growth driven by accelerating Nexobrid sales, advancing late-stage EscharEx trials, and strategic manufacturing investments. The company’s strong cash position and industry partnerships provide a solid foundation for delivering long-term value amid evolving market dynamics.
Industry Read-Through
MediWound’s progress signals increasing industry focus on enzymatic debridement therapies as alternatives to surgical interventions in burn and chronic wound care. The broad collaboration with leading wound care companies highlights a trend toward integrated clinical research partnerships to accelerate innovation. The emphasis on manufacturing scale-up and government stockpiling reflects growing demand for scalable, emergency-ready therapeutic solutions in global healthcare markets. Other biotech firms in enzymatic therapeutics and wound care should monitor MediWound’s regulatory and commercial milestones as indicators of market receptivity and operational challenges in this niche.